Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy

Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.

Alterity Therapeutics has secured positive feedback from the U.S. Food and Drug Administration following a second Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy, a rare neurodegenerative disorder with no approved disease-modifying therapies. The FDA endorsed the company’s chemistry, manufacturing, and control plans for ATH434, supporting manufacturing scale-up and reinforcing readiness to initiate a pivotal Phase 3 trial.

This regulatory alignment marks a key milestone in Alterity’s effort to bring ATH434 to market and reduces a major development risk around product quality and supply for late-stage trials. With an End-of-Phase 2 meeting scheduled for mid-2026, the company is positioning ATH434 as a potential first-in-class treatment for Multiple System Atrophy, a development closely watched by investors and patients given the scarcity of therapeutic options in this indication.

The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, particularly Multiple System Atrophy and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in Phase 2 trials, and the company also operates a broader drug discovery platform targeting underlying neurological disease pathology, with operations based in Melbourne and San Francisco.

Average Trading Volume: 8,215,470

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$108.8M

See more data about ATH stock on TipRanks’ Stock Analysis page.